Renal Cell Carcinoma
Conference Coverage
Cancer patients with TKI-induced hypothyroidism had better survival rates
When it comes to the adverse effects of tyrosine kinase inhibitors, hypothyroidism appears to have a bright side.
Conference Coverage
CheckMate 214: Updated results for RCC focus on PD-L1 expression, QOL
NATIONAL HARBOR, MD. – Benefit from combination immune checkpoint inhibitor treatment for renal cell carcinoma patients was greatest with PD-L1–...
From the Journals
Perioperative blood transfusion linked to worse outcomes in renal cell carcinoma
PBT increased the risk of tumor recurrence, metastatic progression, and death in patients undergoing nephrectomy for RCC.
From the Journals
High EZH2 expression a marker for death risk in RCC
Tumor levels of the oncogenic protein were predictive of death even among patients considered at low or intermediate risk by a standard prognostic...
Conference Coverage
PFS better with first-line pazopanib vs. sorafenib in mRCC
MADRID – The drug sequence matters when it comes to the treatment of advanced or metastatic renal cell carcinoma (mRCC) investigators have found....
Conference Coverage
Checkmate 214: Upfront nivo/ipi bests TKI in advanced RCC
MADRID – Patients with intermediate- or poor-risk advanced clear-cell RCC treated with nivo/ipi did not reach median OS after 32 months’ follow-up...
News
FDA approves biosimilar to bevacizumab
Bevacizumab-awwb is approved for the treatment of adults with certain colorectal, lung, brain, kidney, and cervical cancers.
From the Journals
PROTECT trial: No DFS benefit with adjuvant pazopanib for high-risk RCC
Adjuvant pazopanib provided no disease-free survival benefit compared with placebo in the randomized phase 3 PROTECT trial of patients with...
From the Journals
Pembrolizumab, nivolumab linked to 3% rate of neurologic events
Ten of 347 patients (2.9%) receiving nivolumab or pembrolizumab developed subacute neurologic immune-related adverse events, typically...
Latest News
Tivozanib gets EU approval for advanced RCC
This is the first regulatory approval for tivozanib, which was rejected by the FDA in 2013 for the treatment of RCC.
From the Journals
Adverse effects of PD-1/PD-L1 inhibitors varied by tumor type in systematic review
Patients with melanoma who received PD-1/PD-L1 inhibitors were significantly more likely to develop colitis, diarrhea, pruritus, and rash,...